Clinical Trial

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

Study acronym: NIVIPI-Brain
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, non-randomised, phase II, multicenter clinical trial. 71 stage IV or recurrent, non-small cell lung cancer patients with synchronous brain metastases will be enrolled in this trial to evaluate the efficacy of Nivolumab plus Ipilimumab plus two cycles of platinum-based chemotherapy as first line treatment.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-08-18; most recent amendment 2026-04-29.
Status change: Recruiting → Active, Not Recruiting 2024-08-16
Status change: Not Yet Recruiting → Recruiting 2022-01-25
Trial Details
NCT Number NCT05012254
Lead Sponsor Fundación GECP
Conditions Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer
Enrollment 71 participants
Start Date 2021-11-18
Primary Completion 2027-10-15 (estimated)
Study Completion 2027-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-05